None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ? Histologic confirmed unresectable hilar cholangiocarcinoma or clinically suspicious unresectable hilar cholangiocarcinoma ? Bismuth type II or more degree of bismuth types (II, III, IV) ? predictive suvival period is more than 3 month
Exclusion criteria
Exclusion criteria: ? Not suitable for endoscopic retrograde pancreaticocholedochoscopy ?Over 3 months after endoscopic retrograde pancreaticocholedochoscopy, endoscopic sphincterotomy, or endoscopic retrograde bile duct drainage / endoscopic transnasal bile duct drainage ? uncontrolled blood clotting disorder ? Patients with poor performance status ? Papillary type tumor in the bile duct (Intraductal papillary mucinous neoplasm- bile duct) ? pregnant or lactating status
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The stent patent period | — |
Secondary
| Measure | Time frame |
|---|---|
| The survival period;the technical succsess of metal stent insertion;stents alignment;The clinical success of stent;Early adverse events related to stent insertion;motality related to procedure;Late adverse events related to stent insertion;The reason for stent malfunction;The way for the treatment of stent malfunction | — |
Countries
Korea, Republic of
Contacts
Inha University Hospital